The variation in therapeutic response depending on ATA antibody status, the presence of dyspnea, and the degree of fibrosis confirms the clinical heterogeneity of SSc-ILD and the need to personalize therapy [9,13,15]. This evidence concerns the gene ATM and systemic sclerosis.